Last $30.90 USD
Change Today +0.04 / 0.13%
Volume 1.0M
SGNT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Snapshot

Open
$31.04
Previous Close
$30.86
Day High
$31.45
Day Low
$30.70
52 Week High
09/19/14 - $31.45
52 Week Low
02/5/14 - $17.49
Market Cap
985.6M
Average Volume 10 Days
260.6K
EPS TTM
$0.43
Shares Outstanding
31.9M
EX-Date
--
P/E TM
72.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGENT PHARMACEUTICALS INC (SGNT)

Related News

No related news articles were found.

sagent pharmaceuticals inc (SGNT) Related Businessweek News

No Related Businessweek News Found

sagent pharmaceuticals inc (SGNT) Details

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Docetaxel, an antineoplastic agent used to treat advanced or metastatic breast cancer after chemotherapy failure; Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2013, its product portfolio included 53 marketed products. It sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

269 Employees
Last Reported Date: 03/7/14
Founded in 2006

sagent pharmaceuticals inc (SGNT) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $615.2K
President
Total Annual Compensation: $308.7K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $330.8K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $312.7K
Executive Vice President of National Accounts...
Total Annual Compensation: $287.4K
Compensation as of Fiscal Year 2013.

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals, Inc. Launches the Ketorolac Tromethamine Injection, USP

Sagent Pharmaceuticals, Inc. announced the launch of Ketorolac Tromethamine Injection, USP, a nonsteroidal anti-inflammatory agent, in three preservative-free glass vials. As with all products in Sagent's portfolio, Ketorolac features Sagent's PreventIV Measures(SM) packaging and labeling, designed to help reduce medication errors. Ketorolac Tromethamine Injection, USP is indicated for the short-term (<=5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.

Sagent Pharmaceuticals Announces the Launch of Ibandronate Sodium Injection

Sagent Pharmaceuticals, Inc. announced the launch of Ibandronate Sodium Injection, a bisphosphonate, in a preservative-free, prefilled plastic syringe kit. According to IMS, for the 12 months ending July 2014, the US market for Ibandronate approximated $18 million. As with all products in Sagent's portfolio, Ibandronate features Sagent's PreventIV Measures(SM) packaging and labeling, designed to help reduce medication errors.

Sagent Pharmaceuticals Announces the Reintroduction of Irinotecan Hydrochloride Injection, USP

Sagent Pharmaceuticals, Inc. announced the reintroduction of Irinotecan Hydrochloride Injection, USP, an antineoplastic agent, in two preservative-free amber glass vials. According to IMS, for the 12 months ending June 2014, the US market for Irinotecan approximated $23 million. As with all products in Sagent's portfolio, Irinotecan features Sagent's PreventIV Measures(SM) packaging and labeling, designed to help reduce medication errors. Irinotecan Hydrochloride Injection, USP is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $30.90 USD +0.04

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lannett Co Inc $41.35 USD +0.37
Momenta Pharmaceuticals Inc $11.52 USD -0.08
OraSure Technologies Inc $7.73 USD +0.10
Pfizer Ltd/India 1,663 INR -24.80
SciClone Pharmaceuticals Inc $6.98 USD -0.11
View Industry Companies
 

Industry Analysis

SGNT

Industry Average

Valuation SGNT Industry Range
Price/Earnings 67.6x
Price/Sales 3.7x
Price/Book 4.0x
Price/Cash Flow 67.6x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit www.sagentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.